tldrdailynews.com logo
Tag

Diabetes Drugs

All articles tagged with #diabetes drugs

GLP-1 diabetes drugs linked to slower cancer progression in early study
health9 days ago

GLP-1 diabetes drugs linked to slower cancer progression in early study

An observational analysis of over 10,000 cancer patients who started GLP-1 drugs after diagnosis found slower progression in four of seven cancers, with the strongest effects in lung and breast cancer, compared with a matched group on DPP-4 inhibitors. The study is not peer‑reviewed and cannot prove causation; randomized trials are needed to confirm any anti‑cancer effects. Researchers discuss possible mechanisms, including tumor GLP-1 receptor interactions, interference with glycolysis, and immune modulation, and conclude GLP-1 drugs appear safe for patients with cancer using them for diabetes or obesity, though they are not a cancer therapy.

via NBC News|
#asco#cancer-progression#diabetes-drugs
"Semaglutide Shows Promise in Reducing Alcohol Use Disorder"
health2 years ago

"Semaglutide Shows Promise in Reducing Alcohol Use Disorder"

A study by Case Western Reserve University found that diabetes drugs Wegovy and Ozempic, which contain semaglutide, significantly reduce the risk and recurrence of alcohol-use disorder by 50%-56%. This discovery suggests a potential new treatment for AUD, though further clinical trials are needed to confirm these findings.

via Neuroscience News|
#alcohol-use-disorder#case-western-reserve-university#clinical-trials
Study Finds GLP-1s Like Ozempic and Wegovy Do Not Raise Thyroid Cancer Risk
health2 years ago

Study Finds GLP-1s Like Ozempic and Wegovy Do Not Raise Thyroid Cancer Risk

A large study involving over 145,000 patients prescribed GLP-1 medications like Ozempic and Wegovy found no substantial increase in the risk of developing thyroid cancer. The research, published in BMJ, compared the incidence of thyroid cancer among patients taking GLP-1 drugs and those taking other diabetes medications over an average of four years. While the study couldn't rule out a small increase in risk, it provided strong support that GLP-1 analogues are not significantly associated with an elevated risk of thyroid cancer, contradicting some previous findings.

via Forbes|
#diabetes-drugs#glp-1-medications#health
"Rising Costs of Diabetes and Weight-Loss Drugs Impacting Medicare and Patients"
healthcare2 years ago

"Rising Costs of Diabetes and Weight-Loss Drugs Impacting Medicare and Patients"

Medicare spending on Ozempic and similar diabetes drugs has skyrocketed to $5.7 billion in 2022, up from $57 million in 2018, leading to concerns about potential costs for both the federal government and Medicare enrollees. The pricey medications, including Mounjaro and Rybelsus, have gained popularity for treating diabetes and weight loss, but Medicare is not allowed to cover drugs for weight loss. The KFF analysis found that the combination of high demand and prices for these treatments is likely to place significant pressure on Medicare spending, Part D plan costs, and premiums for Part D coverage. While coverage of these drugs could reduce other healthcare spending, their current prices would likely cost the federal government more than they would save, according to a Congressional Budget Office analysis.

via CNN|
#diabetes-drugs#drug-prices#healthcare
Novo Nordisk's Market Value Hits $500B with Surging Demand for Wegovy
healthcare-pharmaceuticals2 years ago

Novo Nordisk's Market Value Hits $500B with Surging Demand for Wegovy

Novo Nordisk reports its highest annual profit in decades, driven by strong sales of diabetes and obesity drugs like Ozempic and Wegovy. The company is increasing supplies of Wegovy in the US to address shortages, with plans to gradually ramp up supply through 2024. Demand for their GLP-1 drugs has been high, leading to an FDA shortage designation and the emergence of specialized pharmacies making copies of the drug. Novo's annual profit in 2023 reached 83.7 billion Danish kroner, marking its largest annual net profit since 1989, with Ozempic accounting for 41% of total sales and Wegovy bringing in about $4.5 billion in sales.

via The Washington Post|
#diabetes-drugs#fda-shortage#healthcare-pharmaceuticals
Boy George Opens Up About Tummy Tuck and 'Wonder Drug' Mounjaro
entertainment2 years ago

Boy George Opens Up About Tummy Tuck and 'Wonder Drug' Mounjaro

Boy George admits to using the diabetes drug Mounjaro to maintain weight loss after a tummy tuck surgery, revealing struggles with weight and appetite control in his new autobiography "Karma." He also underwent a tummy tuck and hair transplants, calling the plastic surgery the "most painful thing" he's ever done. George's candid admissions come amid a growing trend of celebrities turning to diabetes drugs for weight loss, with Oprah Winfrey also confessing to using medication for weight loss and speaking out against shaming.

via Page Six|
#boy-george#diabetes-drugs#entertainment
Investor Misinterpretation: Eli Lilly's Positive Study Results
pharmaceuticals2 years ago

Investor Misinterpretation: Eli Lilly's Positive Study Results

Despite a significant increase in its share price driven by strong sales of its diabetes drug Mounjaro and potential regulatory approval for Alzheimer's treatment donanemab, Eli Lilly is facing challenges in the long term. The hype around weight-loss drugs is declining, and competitors' drugs are showing higher weight-loss rates. This could negatively impact sales of Eli Lilly's diabetes medicines. The company's high valuation compared to competitors and its lowered earnings guidance for 2023 also raise concerns. As a result, the article recommends an "underperform" rating for Eli Lilly.

via Yahoo Finance|
#competition#diabetes-drugs#eli-lilly
Unmasking the Distorted Reality of off-brand Ozempic
health2 years ago

Unmasking the Distorted Reality of off-brand Ozempic

The demand for injectable diabetes drugs like Ozempic and Wegovy for weight loss has led to a shortage, prompting specialized compounding pharmacies to create their own versions. However, an unregulated market has emerged online, with over two dozen websites selling semaglutide, the active ingredient in these drugs, directly to consumers without the need for doctors or pharmacies. Entrepreneurs are trying to profit from this unregulated market, creating a Wild West scenario for off-brand Ozempic.

via The Washington Post|
#compounding-pharmacies#diabetes-drugs#drug-shortage
Rising Ad Spending and Prescription Surge for Weight-Loss Diabetes Drugs
healthcare2 years ago

Rising Ad Spending and Prescription Surge for Weight-Loss Diabetes Drugs

Drugmakers in the U.S. have spent nearly $500 million on advertising for obesity and diabetes treatments during the first seven months of this year, a 20% increase from the same period last year. The surge in ad spending is driven by the popularity of Novo Nordisk's diabetes drug Ozempic and weight loss drug Wegovy, both of which have seen high demand for their ability to aid weight loss. These drugs, along with other GLP-1 treatments, mimic a gut hormone to suppress appetite. The top four advertised drugs were Ozempic, Wegovy, Rybelsus, and Jardiance, accounting for three-quarters of total ad spending.

via CNBC|
#ad-spending#diabetes-drugs#healthcare
Novo Nordisk Challenges LVMH for Europe's Top Spot
business2 years ago

Novo Nordisk Challenges LVMH for Europe's Top Spot

Novo Nordisk, the Danish drugmaker, briefly surpassed LVMH as Europe's most valuable listed company, ending the French luxury group's 2.5-year reign. Novo Nordisk's success is attributed to the high demand for its diabetes and weight-loss drugs, Ozempic and Wegovy. The company's shares have reached record highs, rising approximately 17% since the announcement of Wegovy's cardiovascular benefits. Novo Nordisk's market capitalization stood at around $424.7 billion, while LVMH's market cap was $420.1 billion. Novo Nordisk's strategy in the obesity drug market has garnered investor appreciation, with the weight loss drug market projected to reach $100 billion in annual sales within a decade.

via Reuters|
#business#diabetes-drugs#luxury-retailer
"US Doctors Advise Against Taking Ozempic Prior to Surgery"
health2 years ago

"US Doctors Advise Against Taking Ozempic Prior to Surgery"

The American Society of Anesthesiologists (ASA) has advised patients taking diabetes and weight loss drugs such as Novo Nordisk's Ozempic and Wegovy or Eli Lilly's Mounjaro to temporarily stop taking them before elective surgery due to potential complications. Anecdotal reports suggest an increased risk of vomiting and aspiration of food into the lungs during anesthesia or sedation. The drugs, known as GLP-1 receptor agonists, delay stomach emptying and reduce hunger, making them popular for weight loss. Patients experiencing gastric side effects while on these drugs are more likely to have residual food in their stomach. The ASA recommends skipping treatment on the day of surgery for daily users and stopping treatment a week before surgery for weekly users. Further research is needed to assess the risks of these treatments during surgery.

via Yahoo News|
#diabetes-drugs#health#mounjaro